Is this the most promising DLL3-targeting therapy yet? Zai Lab advances ADC into Phase 3

What makes Zai Lab’s ADC a potential breakthrough in the fight against small cell lung cancer?

Zai Lab Limited has reported updated Phase 1 results for zocilurtatug pelitecan, formerly known as ZL-1310, an experimental antibody-drug conjugate targeting delta-like ligand 3 (DLL3) in small cell lung cancer. The therapy demonstrated high response rates in relapsed extensive-stage SCLC, particularly in patients with brain metastases, and has now progressed to a global Phase 3 registrational trial. This marks one of the most ambitious late-stage commitments in recent years for the treatment of relapsed small cell lung cancer, a historically treatment-resistant indication with limited innovation since the advent of immune checkpoint inhibitors.

With a design that combines precision targeting with potent cytotoxic payload delivery, zocilurtatug pelitecan is positioning itself as either a first-in-class or best-in-class contender within the DLL3 drug development landscape. For Zai Lab, this candidate not only underscores the company’s ADC ambitions but also signals its intent to compete globally in solid tumor oncology.

How meaningful are the efficacy signals in a heavily pretreated relapsed SCLC population?

The Phase 1 data cut-off as of September 15, 2025, included 115 patients enrolled across six dose levels ranging from 0.8 to 2.8 mg/kg. Nearly all patients had received prior platinum-based chemotherapy and checkpoint inhibitors, with 44 percent receiving two or more lines of therapy. This made the cohort representative of a high-risk, post-standard-of-care population with few therapeutic alternatives. Among 102 patients evaluable for response, the 1.6 mg/kg cohort stood out. In this group, the confirmed overall response rate reached 68 percent, which is highly encouraging in a relapsed setting where historical ORRs hover between 15 and 30 percent.

One of the most compelling subgroups within the trial was patients with brain metastases. Among the 32 patients with known brain involvement, those who had not undergone prior brain radiotherapy exhibited an 80 percent response rate. These results suggest that the drug may be penetrating the blood-brain barrier and acting systemically on intracranial disease, a major hurdle in SCLC management.

Progression-free survival across all dose groups was measured at approximately 5.4 months, and the duration of response was around 6.1 months. Both metrics suggest meaningful disease control for a population with rapidly progressing tumors and few durable treatment options. Adverse events were manageable, with 20 percent of patients experiencing Grade 3 or higher treatment-related toxicities. In the 1.6 mg/kg cohort, this figure dropped to 13 percent, and notably, there were no treatment-related discontinuations.

How has Zai Lab structured its global Phase 3 trial and what are its strategic implications?

Following these promising early-stage results, Zai Lab has launched a global Phase 3 study designed to enroll 665 patients with extensive-stage small cell lung cancer who have relapsed after platinum-based chemotherapy. The trial is randomized and open-label, using investigator’s choice of standard-of-care therapy as the comparator arm. Eligible patients may or may not have received prior DLL3-directed therapy, including bispecifics like Amgen’s tarlatamab.

The primary endpoints are objective response rate, assessed by blinded independent central review, and overall survival. Secondary endpoints include duration of response, progression-free survival, intracranial response rate, and patient-reported quality of life measures. The global nature of the study—spanning North America, Europe, and Asia-Pacific—indicates Zai Lab’s aspirations for regulatory approval in major markets. This also aligns with the company’s recent emphasis on international trial infrastructure and broader global partnerships.

In parallel, Zai Lab has disclosed plans to expand zocilurtatug pelitecan into additional indications. Development programs are being designed for first-line SCLC in combination with chemotherapy or immunotherapy, as well as neuroendocrine carcinoma of extrapulmonary origin. These additional trials are expected to enter the clinic in 2026, depending on readouts from the current registrational study and ongoing safety monitoring.

Why is DLL3 a high-value oncology target and how does Zai Lab’s approach differ from past failures?

DLL3 is an inhibitory Notch ligand that is overexpressed in nearly 80 percent of SCLC tumors while being minimally expressed in normal tissue. This tumor-specific expression makes it an attractive target for therapeutic payload delivery. However, earlier attempts to drug DLL3 have met with disappointment. AbbVie’s Rova-T, the first DLL3-targeting ADC to enter clinical trials, was discontinued after multiple failed studies that revealed limited efficacy and significant toxicity. Zai Lab’s zocilurtatug pelitecan appears to avoid these pitfalls through a redesigned conjugate system. The ADC uses a site-specific conjugation and a novel linker-payload chemistry that offers greater stability and reduces premature payload release, addressing one of the key challenges that led to Rova-T’s failure.

Additionally, the drug’s tolerability profile—particularly the absence of treatment-related discontinuations—provides cautious optimism that Zai Lab has learned from the setbacks of earlier programs. By maintaining therapeutic index and minimizing off-target effects, the company may have succeeded where its predecessors could not.

How does zocilurtatug pelitecan compare to Amgen’s tarlatamab and other DLL3-targeting therapies?

Amgen’s tarlatamab is among the leading DLL3-targeted candidates and employs a different mechanism of action. Rather than using an ADC format, tarlatamab is a bispecific T-cell engager that brings cytotoxic T-cells into proximity with DLL3-expressing tumor cells. While it has shown promising response rates in the 40 to 50 percent range, it has also been associated with cytokine release syndrome and other immune-mediated adverse events. In contrast, zocilurtatug pelitecan does not rely on T-cell engagement and may offer a more manageable safety profile in elderly or immunocompromised patients. Additionally, if the drug’s early signals of activity in brain metastases are confirmed in later trials, it could establish a unique clinical niche.

Other players in the DLL3 space include Boehringer Ingelheim, Sutro Biopharma, and several preclinical efforts, but none have yet matched Zai Lab’s blend of clinical efficacy, safety, and trial momentum. This gives the company a temporary advantage in staking out the ADC end of the DLL3 therapeutic class.

What is the current sentiment among investors and analysts tracking Zai Lab’s oncology strategy?

Investor reaction to the update has been measured but positive. Shares of Zai Lab were recently trading at around US$27.45, showing relative stability after the data release. This suggests that the market views the development as additive rather than transformative—at least until more mature data are available from Phase 3. Analysts have expressed cautious optimism, noting that the drug’s clean safety profile and high response rates in both systemic and intracranial settings represent a meaningful advance over current second-line SCLC options. There is growing recognition that SCLC, long considered a graveyard for drug development, is re-emerging as a viable therapeutic space for targeted modalities. Zai Lab’s progress reinforces the broader trend of ADCs moving into difficult-to-treat solid tumors and is drawing attention from investors focused on oncology platform plays.

What are the key risks as Zai Lab advances this program into the registrational stage?

While the early data are promising, the company faces several hurdles as it moves into Phase 3. First, the response rates observed in Phase 1 were based on small cohorts. In particular, the 68 percent ORR in the 1.6 mg/kg group was derived from just 19 patients. Larger, more diverse populations may produce lower efficacy rates. Second, the history of DLL3-targeting drugs is one of high expectations and subsequent disappointment. Zai Lab must prove not only that its approach is safer but also that it confers durable benefits that translate into overall survival improvement. Third, the regulatory landscape is becoming more competitive. Amgen’s tarlatamab is already further along in late-stage development, and any delay in Zai Lab’s trial could shift the competitive advantage. Commercialization also presents challenges. The SCLC treatment landscape is fragmented, reimbursement is inconsistent, and ADCs are expensive. Unless the drug clearly differentiates itself in terms of cost-effectiveness or clinical utility, market access could be constrained despite clinical success.

How could this program reshape Zai Lab’s broader strategic positioning?

If zocilurtatug pelitecan delivers in Phase 3, it could become the first ADC to gain approval in small cell lung cancer and would anchor Zai Lab’s oncology franchise. Beyond that, it may open the door for the company to expand its ADC platform into other solid tumors, pursue cross-border licensing deals, and attract large-pharma partnerships. The DLL3 program also gives Zai Lab an opportunity to expand beyond its historical Asia-focused portfolio and become a truly global oncology player. With additional trials in neuroendocrine carcinomas and first-line SCLC anticipated in 2026, the company is building a forward pipeline that, if successful, could dramatically raise its valuation and strategic optionality in a consolidating biotech landscape.

Key takeaways: What the updated Zai Lab data and global phase 3 launch mean for SCLC stakeholders

• Zai Lab’s investigational ADC zocilurtatug pelitecan (formerly ZL‑1310) posted a 68% objective response rate in second-line extensive-stage small cell lung cancer (ES‑SCLC) in its Phase 1 trial, with higher responses in patients with brain metastases.

• Among patients with brain metastases who had not received radiotherapy, response rates reached 80%, suggesting potential blood–brain barrier penetration and CNS activity.

• The treatment demonstrated a manageable safety profile, with Grade ≥3 treatment-related adverse events seen in only 13% of patients in the 1.6 mg/kg dose cohort and no toxicity-driven discontinuations.

• Zai Lab has initiated a 665-patient global Phase 3 trial with ORR and overall survival as co-primary endpoints, targeting relapsed ES‑SCLC patients with or without prior DLL3 therapy.

• Zocilurtatug pelitecan is differentiated from Amgen’s DLL3 bispecific tarlatamab by using an antibody-drug conjugate platform rather than T-cell engagement, potentially offering better tolerability.

• The company plans to expand development into first-line SCLC and extrapulmonary neuroendocrine carcinomas in 2026, aiming to build a broader DLL3-targeting franchise.

• Institutional sentiment has been cautiously positive, with ZLAB trading near US$27.45 post-update; investors are awaiting Phase 3 confirmation before re-rating the stock.

• Key risk factors include small Phase 1 cohort size, historical DLL3-targeting drug failures like Rova-T, competition from Amgen’s tarlatamab, and commercialization hurdles in the SCLC landscape.